Synthis Therapeutics
Developing a first in class therapeutic platform that rescues immune function and drives tumor clearance in advanced cancer patients
WHO WE ARE
Dynamic immuno-oncology therapeutics startup in NYC. Synthis’ team is a talented group of scientists with a groundbreaking idea to improve patient care and outcomes. As long-standing tumor immunologists, the team is passionate about the science and therapeutic power behind restoring immune function in cancer patients.
Technology
Synthis Therapeutics is an early-stage biotech company dedicated to the innovation of targeted therapies that harnesses the power of patients’ own immune system to eliminate metastatic cancer. Our novel therapeutic platform evolved from an idea to develop safer and more efficacious therapies that eliminate one of the most immunosuppressive pathways in virtually all cancers, known as TGF-β. By developing therapies that selectively target the immunosuppressive arm of the TGF-β pathway, we can safely drive efficacy and patient survival
TIMELINE
2017
2019
2020
2018
2017
2019
2021
2022
Synthis Tx
platform biology developed
Women In Bio Founders Scholarship Award
1st NCI Ph I SBIR Award
ELab NYC Accelerator Program Fellow
Alexandria LaunchLabs Member Company
2nd NCI Phase I SBIR Award
Alexandria Life Science Summit Pitch
J&J Innovation Showcase Company
Springboard Enterprises Life Science Track Observer
BIO CEO & Investor Conference: NYC-EDC selected company
BIO Conference NIH Sponsored Company Presentation
Endless Frontiers Lab Accelerator Program
Awarded Supplemental SBIR Funding
Seed Investment by VBI
Boehringer Ingelheim Innovation Award Winner & Golden Ticket
Lead drug candidate, SYN101 optimized & selected
Former Immunogen VP, Dr. Bob Lutz, PhD joins as CDO
BioLabs@NYU Langone Member company
Dr. Bill Tanner, PhD MBA joins as interim CFO
Derisked platform with SYN101 mediated in vivo tumor clearance & PD markers
CONTACT US
180 Varick Street, 6th Floor
BioLabs @ NYU Langone
New York, NY 10014